Finck Brian N
Center for Cardiovascular Research, Department of Medicine, Washington University School of Medicine, St Louis, Missouri 63110, USA.
Curr Opin Clin Nutr Metab Care. 2004 Jul;7(4):391-6. doi: 10.1097/01.mco.0000134371.70815.32.
Cardiovascular disease is exceptionally prevalent in patients with diabetes mellitus, which is an emerging pandemic. Unfortunately, the pathogenesis of diabetic myocardial disease is still poorly understood.
Evidence has emerged that perturbed cardiac energy metabolism (excessive dependence on fatty acid utilization and diminished carbohydrate metabolism) plays a role in the development of myocardial dysfunction in diabetes. In support of this, transgenic mice with cardiac-specific activation of the peroxisome proliferator-activated receptor alpha, a nuclear receptor transcription factor that enhances the expression of myriad genes controlling cellular fatty acid utilization, exhibit several classic signatures of the diabetic heart. In particular, the hearts of these mice display: increased import, oxidation, and storage of fatty acids; strong counter-regulatory inhibition of glucose import and oxidation; and cardiomyopathic remodeling and dysfunction. A high-fat diet exacerbates the cardiomyopathic phenotype in peroxisome proliferator-activated receptor alpha transgenic mice in a completely reversible manner. The dysfunctional phenotype and its resolution correlates with levels of several potential toxic mediators, including triglycerides, ceramide, and reactive oxygen species. These findings contrast with several studies demonstrating beneficial effects of peroxisome proliferator-activated receptor alpha ligands in the treatment of type 2 diabetes.
Such studies provide a rationale for greater emphasis on serum lipid-lowering strategies and the control of dietary fat content in the treatment of diabetic cardiomyopathy. Moreover, the use of peroxisome proliferator-activated receptor alpha activators or related compounds as therapeutic agents will require rigorous evaluation of the effects on cardiac function in the diabetic patient.
心血管疾病在糖尿病患者中极为普遍,而糖尿病是一种正在出现的大流行病。不幸的是,糖尿病性心肌病的发病机制仍知之甚少。
有证据表明,心脏能量代谢紊乱(过度依赖脂肪酸利用和碳水化合物代谢减弱)在糖尿病心肌功能障碍的发生中起作用。支持这一观点的是,过氧化物酶体增殖物激活受体α(一种核受体转录因子,可增强控制细胞脂肪酸利用的众多基因的表达)在心脏中特异性激活的转基因小鼠表现出糖尿病心脏的一些典型特征。特别是,这些小鼠的心脏表现为:脂肪酸的摄取、氧化和储存增加;对葡萄糖摄取和氧化的强烈反向调节抑制;以及心肌病变重塑和功能障碍。高脂饮食以完全可逆的方式加剧了过氧化物酶体增殖物激活受体α转基因小鼠的心肌病表型。功能障碍表型及其恢复与几种潜在毒性介质的水平相关,包括甘油三酯、神经酰胺和活性氧。这些发现与几项表明过氧化物酶体增殖物激活受体α配体在治疗2型糖尿病中有有益作用的研究形成对比。
此类研究为在糖尿病性心肌病治疗中更加强调降低血脂策略和控制饮食脂肪含量提供了理论依据。此外,将过氧化物酶体增殖物激活受体α激活剂或相关化合物用作治疗药物需要对糖尿病患者心脏功能的影响进行严格评估。